Study is led by the Institute for Diabetes Research
Study quantifies unprecedented reduction in enteric inflammation, diaper rash and antibiotic use via beneficial gut remodeling.
Largest study to date benchmarks widespread, underrecognized microbiome-linked risk to infant immune system development, antibiotic resistance, acute conditions such as colic and diaper rash
Among the 12 strains of B. infantis analyzed, only B.
Approach is First to Apply Principles of Ecology to Objectively Evaluate Infant Gut Health and Impact of Infant Probiotics
Study aims to investigate whether infant probiotic Evivo can reduce development of early childhood atopic dermatitis, which is implicated in ast
A clinical study published in the journal Pediatric Research shows that colonizing infants with a specific strain of bacteria, activated B.
Breakthrough Study Reveals Activated B. infantis EVC001 as the First Infant Probiotic to Be Effective in the Fight Against Global Health Epidemic
A new study published in mSphere found that children with higher levels of the beneficial bacteria, Bifidobacterium, in their gut microbiome had reduced abundance and lower frequency
Evivo scientists have developed a prototype of the first and only point-of-care screening test designed to identify infants that do not have enough Bifidobacterium to create a stable infant gut microbiome.
Our gastrointestinal tract helps protect our bodies from harmful bacteria, and the protective barrier that lines the walls of the large intestine plays a lead role.
The mix of good and bad bacteria that live in our gut, and the amount of each, makes a big difference in our baby’s health.
Evolve BioSystems, Inc., the leading infant gut microbiome company, today announced that it has comp
Evivo is on a mission to help improve gut health for babies all over the world.
Evolve BioSystems today announced new research that connects elevated infant fecal pH levels to a profound change in the infant gut microbiome, including the disappearance of a beneficial bacterium that may be
Evolve BioSystems today announced positive results from their landmark clinical trial in support of Evivo, an activated form of the beneficial bact
Targeted probiotic supplementation in breastfed infants can significantly reduce the potential for antibiotic resistance, new research presented at the 51st ESPGHAN Annual Meeting.
DAVIS, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Evolve BioSystems, Inc., a microbiome company developing novel solutions to resolve infant gut dysbiosis, is pleased to announce that Evivo™ (activated B. infantis EVC001, ActiBif®) has now been granted regulatory approval for sale in Canada.
U.S. Moms Know There's a Connection Between Breast Milk and the Infant Gut, But Most Don't Know Up To 15% of Breast Milk Nutrients Are Wasted Yet Critical During First Six Months.
Evolve BioSystems, Inc. announces the introduction of Evivo, the first and only probiotic clinically proven to restore a baby's gut microbiome to its original, natural state. Once daily Evivo helps develop a healthy immune system and metabolism to set up babies for healthier lives.
Get the latest updates.
*B. infantis EVC001 out-performs other commercially-available B. infantis strains lacking important functions of the H5 cluster
* excluding Alaska , Hawaii and interternational
Evivo, a live beneficial bacteria, is shipped 2-day delivery to minimize time spent in warmer weather. But don’t worry, Evivo will withstand a wide range of temperatures through the hottest and coldest seasons!
Orders placed after 11:30 am PST Wednesday through Sunday, ship the first business day the following week to ensure your Evivo does not sit in the carrier’s delivery truck or facility over the weekend. Overnight orders placed Monday through Thursday before 11:30 am PST ship the same day.
See our FAQs for more information about Orders, Shipping, & Evivo's Return Policy.
Fast. Free Shipping. Learn More.
Notify me when available